| 000 | 03068nam a22003737a 4500 | ||
|---|---|---|---|
| 008 | 180730s20182018 xxu||||| |||| 00| 0 eng d | ||
| 022 | _a0300-0664 | ||
| 024 | _a10.1111/cen.13806 [doi] | ||
| 040 | _aOvid MEDLINE(R) | ||
| 099 | _a29972703 | ||
| 245 | _aThe Effect of Lithium on the Progression Free and Overall Survival in Patients with Metastatic Differentiated Thyroid Cancer Undergoing Radioactive Iodine Therapy. | ||
| 251 | _aClinical Endocrinology. 2018 Jul 04 | ||
| 252 | _aClin Endocrinol (Oxf). 2018 Jul 04 | ||
| 253 | _aClinical endocrinology | ||
| 260 | _c2018 | ||
| 260 | _fFY2019 | ||
| 266 | _d2018-07-30 | ||
| 520 | _aCONCLUSION: The older age is associated with shorter OS, while disease burden affects OS and PFS in patients with metastatic thyroid cancer. The method of preparation for RAI therapy does not affect the outcome. This article is protected by copyright. All rights reserved. | ||
| 520 | _aCopyright This article is protected by copyright. All rights reserved. | ||
| 520 | _aDESIGN/PATIENTS/MEASUREMENTS: We performed a cohort study comparing overall survival (OS) and progression-free survival (PFS) between the three groups: THW(n=52), THW+Li (n=41) and rhTSH (n=42). Kaplan-Meier analyses were performed to compare OS and PFS between the groups. Cox proportional hazards regression model with a stepwise variable selection was performed to study the contribution of age, gender, histology, TNM status, a location of distant metastases and RAI dose. | ||
| 520 | _aOBJECTIVE: Pretreatment with lithium (Li) is associated with an increased residence time of radioactive iodine (RAI) in differentiated thyroid cancer (DTC) metastases. There are no data translating this observation into long-term outcomes. The study goal was to compare the efficacy of three methods of preparation for RAI therapy in metastatic DTC - thyroid hormone withdrawal (THW), THW with pre-treatment with Li (THW+Li), and recombinant human TSH (rhTSH). | ||
| 520 | _aRESULTS: During the follow up of median 5.1 (IQR=3.0-8.1) years, 52% of patients had disease progression and 12.6% died. Although THW+Li group was characterized by the longest OS (p=0.007), only age (HR 1.05, CI 1.01-1.09, p=0.01) and widespread disease (HR3.8, CI 1.2-11.8, p=0.02) were found to affect OS in a multivariate model. There was no difference in PFS between the groups (p=0.47). Presence of distant metastases limited to the lungs only was associated with longer PFS (PFS HR 0.35, CI 0.20-0.60, p=0.0002). | ||
| 546 | _aEnglish | ||
| 650 | _aIN PROCESS -- NOT YET INDEXED | ||
| 651 | _aMedStar Washington Hospital Center | ||
| 656 | _aMedicine/Endocrinology | ||
| 657 | _aJournal Article | ||
| 700 | _aBurman, Kenneth D | ||
| 700 | _aLima, Cristiane | ||
| 700 | _aWartofsky, Leonard | ||
| 790 | _aAuh S, Burman K, Cochran C, Kebebew E, Klubo-Gwiezdzinska J, Lima C, Luo H, Reynolds J, Skarulis M, Tobey A, Wartofsky L, Zemskova M | ||
| 856 |
_uhttps://dx.doi.org/10.1111/cen.13806 _zhttps://dx.doi.org/10.1111/cen.13806 |
||
| 942 |
_cART _dArticle |
||
| 999 |
_c3597 _d3597 |
||